Can You Take Ketamine with Escitalopram?

Severity assessment

Major. The combination significantly increases the risk of central nervous system (CNS) depression, including excessive sedation and respiratory depression, and potentially serotonin syndrome.

Mechanism (plain English)

Escitalopram is a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain. Serotonin is a neurotransmitter that helps regulate mood. Ketamine, while primarily known as an N-methyl-D-aspartate (NMDA) receptor antagonist, also influences other neurotransmitter systems, including serotonin. When escitalopram and ketamine are used together, there is an additive effect on serotonin levels, which can lead to an excessive accumulation of serotonin in the brain, resulting in serotonin syndrome. Additionally, both medications can cause central nervous system depression, leading to increased sedation, dizziness, and potentially dangerous respiratory depression.

Evidence level

Regulator-flagged. The FDA prescribing information for both drugs highlights risks associated with concomitant use of CNS depressants and serotonergic agents. [1, 2]

Top regulator advisories (cite verbatim or close paraphrase)

• TGA (Australia): No pair-specific public advisory found. Applicable product information for escitalopram (e.g., Lexapro) warns about serotonin syndrome with other serotonergic agents. Applicable product information for ketamine (e.g., Ketalar) warns about CNS depression with other CNS depressants.
• MHRA / NICE (UK): No pair-specific public advisory found. The BNF advises caution with concomitant use of serotonergic drugs due to risk of serotonin syndrome. Ketamine product information advises caution with other CNS depressants.
• FDA / CDC (US): The FDA prescribing information for escitalopram (Lexapro) states: "Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. If it occurs, discontinue Lexapro and initiate supportive treatment (4, 5.2)" [2]. The FDA prescribing information for esketamine (SPRAVATO), a derivative of ketamine, indicates it is used in conjunction with an oral antidepressant, but also warns about sedation, dissociation, and respiratory depression [1]. It also lists drug interactions with Central Nervous System Depressants [1].
• EMA (Europe): No pair-specific public advisory found. EMA product information for escitalopram warns of serotonin syndrome risk with other serotonergic drugs. Ketamine product information warns of additive CNS depression with other CNS depressants.

Clinical risk factors that elevate the danger

• Concomitant use of other serotonergic agents: Medications like triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John’s Wort can further increase serotonin levels, exacerbating the risk of serotonin syndrome. [2]
• Concomitant use of other CNS depressants: Alcohol, benzodiazepines, opioids, and other sedatives can enhance the CNS depressant effects of ketamine and escitalopram, leading to increased sedation and respiratory depression. [1]
• Elderly patients: Older individuals may be more susceptible to the CNS depressant effects and cognitive impairment. [3]
• Patients with cardiovascular or cerebrovascular conditions: Ketamine can increase blood pressure, posing a serious risk in these patients. [1]
• Patients with a history of seizures: Escitalopram should be used with caution in such patients. [2]
• Patients with hepatic impairment: Metabolism of both drugs can be affected, potentially leading to higher drug levels. [2]

What a patient should be told

• Understand the risks: Taking escitalopram and ketamine together can make you very drowsy, confused, and can slow your breathing. There's also a risk of a serious condition called serotonin syndrome, which can cause symptoms like agitation, hallucinations, rapid heart rate, and fever.
• Do not stop suddenly: If you are taking these medications, do not stop either one without talking to your doctor or pharmacist first. Suddenly stopping escitalopram can cause withdrawal symptoms.
• Watch for warning signs: Be aware of symptoms like unusual agitation, restlessness, confusion, rapid heart rate, sweating, muscle stiffness, twitching, or uncontrolled movements. Also, watch for excessive drowsiness, difficulty breathing, or feeling unusually unwell. If you experience any of these, seek immediate medical attention.
• Discuss alternatives: Talk to your doctor or pharmacist about all medications you are taking, including over-the-counter drugs, supplements, and herbal remedies. They can help determine if there are safer alternatives or if adjustments to your treatment plan are needed.
• Urgent care triggers: If you or someone you know experiences severe confusion, seizures, very high fever, irregular heartbeat, or difficulty breathing, call emergency services immediately.

Top 3 sources (with full citation)

1. SPRAVATO (esketamine) nasal spray, CIII, Prescribing Information. Janssen Pharmaceuticals, Inc. Revised March 2026. Available at: https://www.jnjlabels.com/package-insert/product-monograph/prescribing-information/SPRAVATO-pi.pdf
2. LEXAPRO (escitalopram) tablets, for oral use, oral solution, Prescribing Information. AbbVie Inc. Revised May 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021323s055,021365s039lbl.pdf
3. Escitalopram and Ketamine. Drugs.com. Available at: https://www.drugs.com/drug-interactions/escitalopram-with-ketamine-1013-0-1411-0.html

Notes for the reviewing pharmacist

The interaction between escitalopram and ketamine primarily involves two key concerns: the potential for serotonin syndrome due to the serotonergic activity of both agents (though ketamine's contribution is less direct than traditional serotonergic drugs), and additive central nervous system (CNS) depression. While esketamine (the S-enantiomer of ketamine) is approved for use in conjunction with oral antidepressants, including SSRIs, the prescribing information emphasizes careful monitoring for sedation, dissociation, and respiratory depression. The risk of serotonin syndrome with ketamine is generally considered theoretical or case-report-supported rather than regulator-flagged, as ketamine is not a direct serotonergic agent like SSRIs. However, its indirect effects on serotonin pathways warrant caution. Pharmacists should be vigilant for signs of both CNS depression and serotonin syndrome, especially during initiation or dose adjustments. Patient education should clearly differentiate between expected side effects of ketamine (e.g., dissociation, sedation) and symptoms that may indicate a more serious interaction. Emphasize the importance of adherence to prescribed administration protocols for ketamine, particularly the supervised setting and post-administration monitoring. It is crucial to ensure patients understand not to self-administer or alter dosages. The evolving understanding of ketamine's mechanism, particularly its interaction with serotonergic systems, means pharmacists should stay updated on emerging evidence and guidelines. Consideration should also be given to the patient's overall medication regimen, comorbidities, and individual risk factors for CNS depression and serotonin syndrome.